دورية أكاديمية
أعرض في EDS

Risk of COVID-19 re-infection and its predictors (CORES): protocol for a community-based longitudinal cohort study in Vellore, India.

التفاصيل البيبلوغرافية
العنوان: Risk of COVID-19 re-infection and its predictors (CORES): protocol for a community-based longitudinal cohort study in Vellore, India.
المؤلفون: Madhavan R; The Wellcome Trust Research Laboratory, Division of Gastrointestinal sciences, Christian Medical College and Hospital, Vellore, Tamil Nadu, India., Paul JS; Department of Community Health and Development, Christian Medical College and Hospital, Vellore, Tamil Nadu, India., Babji S; The Wellcome Trust Research Laboratory, Division of Gastrointestinal sciences, Christian Medical College and Hospital, Vellore, Tamil Nadu, India., Kumar D; The Wellcome Trust Research Laboratory, Division of Gastrointestinal sciences, Christian Medical College and Hospital, Vellore, Tamil Nadu, India., Prabhu SB; The Wellcome Trust Research Laboratory, Division of Gastrointestinal sciences, Christian Medical College and Hospital, Vellore, Tamil Nadu, India., Pulleri HK; COVID-19 Testing and Sequencing lab, Institute for stem cell science and Regenerative Medicine (inStem), Bangalore, Karnataka, India., Annadorai R; COVID-19 Testing and Sequencing lab, Institute for stem cell science and Regenerative Medicine (inStem), Bangalore, Karnataka, India., Gowda SR; COVID-19 Testing and Sequencing lab, Institute for stem cell science and Regenerative Medicine (inStem), Bangalore, Karnataka, India., John J; Department of Community Health and Development, Christian Medical College and Hospital, Vellore, Tamil Nadu, India., Kang G; The Wellcome Trust Research Laboratory, Division of Gastrointestinal sciences, Christian Medical College and Hospital, Vellore, Tamil Nadu, India gkang@cmcvellore.ac.in.
المصدر: BMJ open [BMJ Open] 2022 May 24; Vol. 12 (5), pp. e059869. Date of Electronic Publication: 2022 May 24.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-6055 (Electronic) Linking ISSN: 20446055 NLM ISO Abbreviation: BMJ Open Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : BMJ Publishing Group Ltd, 2011-
مواضيع طبية MeSH: COVID-19*/epidemiology, Adult ; Cohort Studies ; Humans ; Longitudinal Studies ; Reinfection/epidemiology ; SARS-CoV-2 ; Seroepidemiologic Studies ; Spike Glycoprotein, Coronavirus
مستخلص: Introduction: The incidence of SARS-CoV-2 re-infection has not been widely evaluated in low-income and middle-income countries. Understanding immune responses elicited by SARS-CoV-2 natural infection and factors that lead to re-infection in a community setting is important for public health policy. We aim to investigate the risk of primary infection and re-infection among those without and with evidence of prior infection as defined by the presence of antibodies to SARS-CoV-2 spike protein.
Methods and Analysis: A baseline seroprevalence survey will test for SARS-CoV-2 antibodies among healthy adults in Vellore, India. Based on an expected seropositivity rate of 50% in the general population, with annual attack rates of 12%, 6%, 4.8% and 4% among those unvaccinated and seronegative, vaccinated and seronegative, unvaccinated and seropositive, and vaccinated and seropositive, respectively, we will recruit 1200 adults who will be followed up for a total of 24 months. Weekly self-collected saliva samples will be tested by reverse transcription-PCR (RT-PCR) to detect SARS-CoV-2 infections, for a period of 1 year. For any person testing RT-PCR positive, blood samples will be collected within 2 days of RT-PCR positivity and on days 30 and 90 to assess the kinetics and longevity of the antibody responses, B cell memory and T cell memory post-infection. The data will be analysed to estimate seroprevalence at baseline and over time, the risk factors for infection, rates of primary infection and re-infection, and provide a comparison of the rates across groups based on infection and vaccination status.
Ethics and Dissemination: The study has been approved by the Institutional Review Board (IRB No: 13585) of Christian Medical College and Hospital, Vellore. The results of the study will be made available through journal publications and conference presentations.
Trial Registration Number: Central Trial Registry of India: CTRI/2020/11/029438.
Competing Interests: Competing interests: None declared.
(© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.)
References: Lancet Infect Dis. 2021 Jan;21(1):52-58. (PMID: 33058797)
Vaccine. 2016 Apr 12;34(17):2008-14. (PMID: 26954467)
Cell. 2020 Nov 12;183(4):996-1012.e19. (PMID: 33010815)
J Clin Microbiol. 2010 Aug;48(8):2940-7. (PMID: 20554810)
N Engl J Med. 2007 Sep 13;357(11):1162-3. (PMID: 17855683)
Int J Infect Dis. 2021 Nov;112:8-12. (PMID: 34508860)
Nature. 2020 Nov;587(7833):270-274. (PMID: 32726801)
Science. 2020 Oct 2;370(6512):89-94. (PMID: 32753554)
Lancet. 2021 May 29;397(10289):2043-2046. (PMID: 33991480)
Clin Infect Dis. 2022 Jan 29;74(2):294-300. (PMID: 33895814)
Microbiol Spectr. 2021 Oct 31;9(2):e0059021. (PMID: 34550000)
Clin Infect Dis. 2021 Nov 2;73(9):e2946-e2951. (PMID: 32840608)
Epidemiol Infect. 1990 Oct;105(2):435-46. (PMID: 2170159)
N Engl J Med. 2022 Mar 31;386(13):1207-1220. (PMID: 35172051)
Science. 2021 Feb 5;371(6529):. (PMID: 33408181)
Signal Transduct Target Ther. 2020 Sep 2;5(1):180. (PMID: 32879307)
PLoS One. 2021 Feb 23;16(2):e0243183. (PMID: 33621263)
Lancet. 2020 Nov 14;396(10262):1595-1606. (PMID: 33065034)
معلومات مُعتمدة: INV-024915 United States GATES Bill & Melinda Gates Foundation
فهرسة مساهمة: Keywords: COVID-19; immunology; public health
المشرفين على المادة: 0 (Spike Glycoprotein, Coronavirus)
0 (spike protein, SARS-CoV-2)
تواريخ الأحداث: Date Created: 20220525 Date Completed: 20220527 Latest Revision: 20240923
رمز التحديث: 20240923
مُعرف محوري في PubMed: PMC9130666
DOI: 10.1136/bmjopen-2021-059869
PMID: 35613771
قاعدة البيانات: MEDLINE
الوصف
تدمد:2044-6055
DOI:10.1136/bmjopen-2021-059869